A Promising New Drug for Alzheimer’s Disease

In January, the Food and Drug Administration (FDA) approved Leqembi (lecanemab) for the treatment of early-stage Alzheimer’s disease. While not an all-out game-changer, the new drug represents a new approach—one that is of real benefit to patients, says Dr. Matthew Fink, Neurologist in Chief and Louis and Gertrude Feil Professor and Chairman of the Department of Neurology at Weill Cornell Medicine.

Congratulations to the Weill Cornell Medicine Physicians Chosen as the Best in the Country and the New York Metropolitan Area

This year, once again, Weill Cornell Medicine’s physicians are among the best in the country. So say their peers—250,000 leading doctors nationwide—who reported their picks to Castle Connolly Medical Ltd., a New York City research and information company that publishes the annual guidebooks America’s Top Doctors and Top Doctors: New York Metro Area.

Podcast: Alzheimer’s Disease Awareness

In this episode of Back to Health, Kellyann Niotis, M.D., discusses Alzheimer’s Disease (AD).

Podcast: Women's Brain Health

In this episode of Women's Health Wednesday series of Back to Health, Silky Pahlajani, M.D. discusses women's brain health.

Alzheimer’s Disease May Be Preventable

Memory loss. Confusion. Trouble managing money and daily tasks. Could it be a vitamin deficiency or medication side effects? Yes. It could also be Alzheimer’s disease.